These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29030717)

  • 1. Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection.
    Winhusen T; Feaster DJ; Duan R; Brown JL; Daar ES; Mandler R; Metsch LR
    AIDS Behav; 2018 Jun; 22(6):2026-2032. PubMed ID: 29030717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between cigarette smoking, virologic suppression, and CD4+ lymphocyte count in HIV-Infected Russian women.
    Brown JL; Winhusen T; DiClemente RJ; Sales JM; Rose ES; Safonova P; Levina O; Belyakov N; Rassokhin VV
    AIDS Care; 2017 Sep; 29(9):1102-1106. PubMed ID: 28497980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of monitoring antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals.
    Vogler IH; Alfieri DF; Gianjacomo HDB; Almeida ERD; Reiche EMV
    Cad Saude Publica; 2018 Oct; 34(10):e00009618. PubMed ID: 30365742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
    Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
    Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010-2015.
    Lesko CR; Lau B; Chander G; Moore RD
    AIDS Behav; 2018 Nov; 22(11):3443-3450. PubMed ID: 29541913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
    Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
    AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.